Mitsubishi Chemical Research Corporation (MCR) provides non-clinical studies in their own GLP-compliant facilities. Leveraging its extensive experience and specialized expertise, MCR supports the safety evaluation of chemical substances as well as supports for compliance with regulatory requirements in foreign countries.
MCR operates their own GLP-compliant facilities and offers an integrated range of regulatory submission studies that meet domestic and international requirements. With long-standing expertise, the company provides tailored study proposals based on the properties and intended applications of test substances.
Their capabilities include biodegradability studies, bioaccumulation studies, ecological impact testing, and polymer-related testing. In addition to in-house studies, certain testing can be conducted in collaboration with external specialized institutions. Monitoring and quality oversight are also available.
MCR provides comprehensive support for registration applications under various chemical regulatory standards, including Japan’s Chemical Substances Control Law and Industrial Safety and Health Act, the U.S. TSCA, and the EU REACH regulation. Through close cooperation with local representatives, MCR assists with the planning of efficient submission strategies and communication with regulatory authorities.
The company has gained recognition as a highly trusted partner for regulatory compliances. They offer support for GHS classification, SDS preparation, risk assessment, and voluntary environmental management such as wastewater management.
A defining strength of MCR is its extensive record of projects commissioned by Japanese government agencies such as the Ministry of Economy, Trade and Industry, the Ministry of the Environment, the Japan Patent Office, and the Ministry of Agriculture, Forestry and Fisheries. MCR has demonstrated high-level expertise across a broad industries, including chemical substance safety assessment, risk evaluation, and technology trend analysis.
They have contracted numerous public research projects with their specialty, reliability and flexibility.
As part of their ecological impact assessment services, MCR provides models with algae, Daphnia magna, and fish. These models are suitable for evaluating the environmental effects of pesticides and chemical products on aquatic ecosystems and play an essential role in environmental risk assessment.
Comprehensive study designs can be incorporated with biodegradability and bioaccumulation tests, enabling compliance with regulatory requirements in various countries. High-quality, GLP-compliant data can be generated for test substances across various development stages—from early stage to clinical submission.
Reference: MCR official website https://www.mitsubishichem-res.co.jp/psa/
MCR provides a wide variety of non-clinical studies, including genotoxicity testing (Ames test, chromosomal aberration test, micronucleus test), acute and repeated-dose toxicity studies, and skin irritation and sensitization studies.
For human health impact assessments, they can support the evaluation of special substances, such as reaction products and gas state material. GLP-compliant studies can be accommodated with highly reliable domestic and international partnered institutions.
They offer tailored study proposals, including CSR-related activity, in compliance with the MARPOL Convention, and environmental risk assessment of pharmaceutical drugs.
Reference: MCR official website https://www.mitsubishichem-res.co.jp/psa/hht_test.html
| Address | 5F Yotsuya TN Building, 16-1 Samoncho, Shinjuku-ku, Tokyo |
|---|---|
| Tel | 03-6893-6410 |
| Website | https://www.mitsubishichem-res.co.jp/ |
In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D.
In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening.
Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.